Kabeer Aziz - Mar 29, 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director, 10%+ Owner
Signature
/s/ Lucy Day, Attorney-in-Fact for Kabeer Aziz
Stock symbol
ANTX
Transactions as of
Mar 29, 2022
Transactions value $
$2,499,990
Form type
4
Date filed
3/31/2022, 08:15 PM
Previous filing
Mar 24, 2022
Next filing
May 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Conversion of derivative security +1.65M 1.65M Mar 29, 2022 By Adjuvant Global Health Technology Fund, L.P. F1, F2
transaction ANTX Common Stock Conversion of derivative security +312K 312K Mar 29, 2022 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
transaction ANTX Common Stock Conversion of derivative security +392K +23.76% 2.04M Mar 29, 2022 By Adjuvant Global Health Technology Fund, L.P. F1, F2
transaction ANTX Common Stock Conversion of derivative security +74.2K +23.76% 387K Mar 29, 2022 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
transaction ANTX Common Stock Purchase $2.5M +167K +8.15% $15.00 2.21M Mar 29, 2022 By Adjuvant Global Health Technology Fund, L.P. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Series A Convertible Preferred Stock Conversion of derivative security $0 -1.65M -100% $0.00* 0 Mar 29, 2022 Common Stock 1.65M By Adjuvant Global Health Technology Fund, L.P. F1, F2
transaction ANTX Series A Convertible Preferred Stock Conversion of derivative security $0 -312K -100% $0.00* 0 Mar 29, 2022 Common Stock 312K By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
transaction ANTX Series B Convertible Preferred Stock Conversion of derivative security $0 -392K -100% $0.00* 0 Mar 29, 2022 Common Stock 392K By Adjuvant Global Health Technology Fund, L.P. F1, F2
transaction ANTX Series B Convertible Preferred Stock Conversion of derivative security $0 -74.2K -100% $0.00* 0 Mar 29, 2022 Common Stock 74.2K By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
F2 Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F3 Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.